Financial Analysis: ProSomnus (OSA) and Its Competitors

ProSomnus (NASDAQ:OSA) is one of 143 publicly-traded companies in the “Medical Devices” industry, but how does it contrast to its peers? We will compare ProSomnus to similar companies based on the strength of its profitability, dividends, risk, valuation, earnings, institutional ownership and analyst recommendations.

Profitability

This table compares ProSomnus and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-79.10%	-63.90%	-21.64%

Volatility & Risk

ProSomnus has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ peers have a beta of 0.86, suggesting that their average stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ProSomnus and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	3	0	2.75
ProSomnus Competitors	308	1137	1352	40	2.40

ProSomnus currently has a consensus price target of $2.33, suggesting a potential upside of 345.38%. As a group, “Medical Devices” companies have a potential upside of 47.78%. Given ProSomnus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ProSomnus is more favorable than its peers.

Insider & Institutional Ownership

70.0% of ProSomnus shares are held by institutional investors. Comparatively, 26.4% of shares of all “Medical Devices” companies are held by institutional investors. 7.7% of ProSomnus shares are held by company insiders. Comparatively, 24.2% of shares of all “Medical Devices” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares ProSomnus and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.34
ProSomnus Competitors	$471.36 million	$14.70 million	90.69

ProSomnus’ peers have higher revenue and earnings than ProSomnus. ProSomnus is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

ProSomnus peers beat ProSomnus on 8 of the 13 factors compared.

ProSomnus Company Profile

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.